Clopidogrel with or without omeprazole in coronary artery disease.
about
Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidenceClopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designsOverutilization of proton-pump inhibitors: what the clinician needs to knowSafety of Digestive Endoscopy following Acute Coronary Syndrome: A Systematic ReviewCurrent status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implicationsPharmacodynamic impacts of proton pump inhibitors on the efficacy of clopidogrel in vivo--a systematic reviewClopidogrel and proton pump inhibitors--where do we stand in 2012?Current perspectives in NSAID-induced gastropathyTreatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapyEsomeprazole and aspirin fixed combination for the prevention of cardiovascular eventsExpert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapyPotential for developing purinergic drugs for gastrointestinal diseasesProton pump inhibitors in prevention of low-dose aspirin-associated upper gastrointestinal injuriesStress ulcer prophylaxis in the intensive care unit: is it indicated? A topical systematic reviewEffects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysisEffects of Clopidogrel and Proton Pump Inhibitors on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus after Drug-Eluting Stent Implantation: A Nationwide Cohort StudyProton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General PopulationEvidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.Dexlansoprazole MR for the management of gastroesophageal reflux disease.Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.Clopidogrel: the data, the experience, and the controversies.Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies.Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors.Platelet distribution width as the prognostic marker in coronary bifurcation treatment.Recent advances in antithrombotic therapy after acute coronary syndrome.The potential interaction between clopidogrel and proton pump inhibitors: a systematic review.Pantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in KoreaAntiplatelet drug interactions with proton pump inhibitorsImpact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.Risk score to predict gastrointestinal bleeding after acute ischemic strokeCombined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention.One fifth of hospitalizations for peptic ulcer-related bleeding are potentially preventable.Consensus on control of risky nonvariceal upper gastrointestinal bleeding in Taiwan with National Health Insurance.Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions.Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial.Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysisAssociation between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis.Prevention of upper gastrointestinal haemorrhage: current controversies and clinical guidanceState-of-the-art management of acute bleeding peptic ulcer disease.
P2860
Q24608981-83551E9E-429F-4FE1-81FC-C8EC0E288C51Q24633087-488611C8-D50C-44CA-B180-C22313419171Q24634086-D4DBF032-F7C4-42A0-A525-710E1D8B8216Q26742094-A6057F5A-CD5B-49C4-A5E1-0F84141D7913Q26771106-17FB8AB6-71BF-4E44-A46F-84BFEF549595Q26822474-14CBBC04-8F65-4619-9374-602EA52BF3E0Q26825728-D53B01E3-A8FA-4C36-A2E7-F0A4BC7AE03EQ26827673-B1646AAE-41FF-4E15-B647-7BEA3048E152Q26866350-B6F9BB16-B397-42F9-998A-A152EB4D7689Q26995752-756E3373-486E-49ED-A8CA-BA399B4E9B05Q26998331-3F728B16-34D8-4C0D-86DE-1926944F6929Q27000719-D3E80B00-CF7E-4F62-BEC6-62D61112260EQ27004834-02A42CF8-9AF4-46A1-B849-C373D0084B59Q28287257-854B469A-89A2-4D72-90A1-95222910147AQ28480610-C5BA579D-1A25-484E-9C3C-994EF8E5F770Q28547539-303E8CB6-C738-498D-BD11-165A81209996Q28548045-D1BE10C1-BCFA-4315-BD57-672FBEA6A75EQ30249468-4D4D11A2-0CF1-4725-8B3D-1F409FD43698Q30421742-917F0D24-B049-4CF0-B9F1-DBD62784640DQ30453948-A2FBCBF9-42CA-4D5B-90E2-2F371863C963Q30457290-9D924AC0-CCE5-419B-A675-D2EB61BF33F3Q30573045-D2DC7D44-DA70-4811-9AC3-47956F5BA880Q30928614-3DC3FA7D-A9C4-4703-845C-F85BE3D50C88Q31157434-29E8CC45-E82B-4A43-88F1-C19F593B37C4Q33442212-A11B9CEA-F99B-4790-9F0A-3E5A650DF6F0Q33590548-DAAC5BDB-C902-4B3F-879E-B03EBA580F83Q33763929-A9EAE121-8800-4A40-BB47-CA34A5CC8B0FQ33853179-5EBB3B4F-7827-4E83-A594-7467F60D1044Q33948811-65700446-9C06-417A-95BA-8FB0DB7FD6B8Q33982372-38D225E0-6616-4A10-965B-260DE753D0E7Q33997632-76C190ED-7CC1-472C-8E64-353F1706D38FQ33997642-CC33E3ED-E2C1-46EE-9818-592FCD75158FQ34036732-37E3C479-B1B8-4970-8300-B30953C6C2BFQ34100357-492827C1-40EB-452C-A004-4742467BFA40Q34161006-4BF989BA-58A8-4FE7-A434-8458766AC5D5Q34169062-FAD46F8A-6997-4A5E-B934-DFFD2B24DFF1Q34486149-BD1A6174-DDB0-46AD-9659-4030915DF917Q34510524-04B5A260-E00D-43A0-A251-78FCE6D89BF6Q34655792-D5B124B0-8A5E-49C8-83B8-4B8E1C719D9DQ34656150-0AC52105-7E8B-44B6-ADBC-E219278D6901
P2860
Clopidogrel with or without omeprazole in coronary artery disease.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Clopidogrel with or without omeprazole in coronary artery disease.
@ast
Clopidogrel with or without omeprazole in coronary artery disease.
@en
Clopidogrel with or without omeprazole in coronary artery disease.
@nl
type
label
Clopidogrel with or without omeprazole in coronary artery disease.
@ast
Clopidogrel with or without omeprazole in coronary artery disease.
@en
Clopidogrel with or without omeprazole in coronary artery disease.
@nl
prefLabel
Clopidogrel with or without omeprazole in coronary artery disease.
@ast
Clopidogrel with or without omeprazole in coronary artery disease.
@en
Clopidogrel with or without omeprazole in coronary artery disease.
@nl
P2093
P356
P1476
Clopidogrel with or without omeprazole in coronary artery disease.
@en
P2093
Angel Lanas
Benjamin M Scirica
Byron L Cryer
COGENT Investigators
Charles F Contant
Christopher P Cannon
Deepak L Bhatt
Loren Laine
Marc Cohen
Mark A Goldsmith
P304
P356
10.1056/NEJMOA1007964
P407
P577
2010-10-06T00:00:00Z